Hoth Therapeutics, a trial-stage biopharmaceutical company, has allocated up to $1 million in Bitcoin. This move is part of their strategy to leverage the cryptocurrency's potential as a store of wealth and a hedge against inflation.
The investment comes amid a backdrop of growing interest in Bitcoin and other digital assets, particularly following the reelection of Donald Trump as U.S. President. Institutional adoption is on the rise, which likely influenced Hoth Therapeutics' decision.
As Bitcoin continues to gain traction among institutional investors, companies like Hoth Therapeutics are positioning themselves to benefit from its potential for long-term value appreciation.
